PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
73.82
+1.34 (1.85%)
At close: Nov 11, 2025, 4:00 PM EST
74.00
+0.18 (0.24%)
After-hours: Nov 11, 2025, 6:56 PM EST
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover PTC Therapeutics stock have a consensus rating of "Buy" and an average price target of $73.24, which forecasts a -0.79% decrease in the stock price over the next year. The lowest target is $45 and the highest is $118.
Price Target: $73.24 (-0.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Hold | 3 | 3 | 3 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 14 | 14 | 14 | 14 | 15 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $46 → $68 | Hold | Maintains | $46 → $68 | -7.88% | Nov 6, 2025 |
| Citigroup | Citigroup | Hold Maintains $50 → $75 | Hold | Maintains | $50 → $75 | +1.60% | Nov 5, 2025 |
| TD Cowen | TD Cowen | Hold Maintains $50 → $63 | Hold | Maintains | $50 → $63 | -14.66% | Nov 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $70 → $82 | Buy | Maintains | $70 → $82 | +11.08% | Nov 5, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $44 → $50 | Strong Sell | Maintains | $44 → $50 | -32.27% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
1.77B
from 806.78M
Increased by 119.02%
Revenue Next Year
883.34M
from 1.77B
Decreased by -50.01%
EPS This Year
7.54
from -4.73
EPS Next Year
-3.48
from 7.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.9B | 1.2B | |||
| Avg | 1.8B | 883.3M | |||
| Low | 1.6B | 521.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 141.3% | -34.5% | |||
| Avg | 119.0% | -50.0% | |||
| Low | 101.8% | -70.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.19 | -0.52 | |||
| Avg | 7.54 | -3.48 | |||
| Low | 3.82 | -8.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.